Clinical trials: Psychotic Disorder
Mental Disorder
Improving Access to Psychiatric Care for Patients in Primary Care
Getting a consultation with a psychiatrist within an appropriate time is one of the main issues reported by general practitioners (GP) for patients suffering from mental disorders in primary care.
- Trial name
- DSPP-PSY (NCT03508518)
- Testing
- Shared care device in psychiatry (DSPP), Usual Care
- Where
- France
- Volunteers
- 151 people
- Sponsor
- University Hospital, Toulouse
Schizophrenia
Treatment on Iatrogenic Weight Gain and Dyslipidaemia Associated With Olanzapine
Olanzapine is one of the most effective and best tolerated of the atypical antipsychotics, but it is also particularly associated with weight gain and metabolic problems.
- Trial name
- GWMD09126 (NCT01491490)
- Testing
- GWP42003 : GWP42004 (40:1)
- Where
- 6 sites in United Kingdom
- Volunteers
- 2 people
- Sponsor
- GW Research Ltd
Schizophrenia
A Study of Elpipodect (MK-8189) in Participants With Schizophrenia (MK-8189-014)
The primary purpose of this study is to assess the safety and tolerability of multiple ascending doses of elpipodect in participants with schizophrenia.
- Trial name
- NCT05406440
- Testing
- Elpipodect
- Where
- 3 sites in United States
- Volunteers
- 53 people
- Sponsor
- Merck Sharp & Dohme LLC
Psychosis
Narrative Identity and Its Relationship to Subjective Multidimensional Well-being in First Episode Psychosis
The transition between adolescence and adulthood (generally defined as ages 18 to 25) is a key developmental window for narrative identity and psychotic disorders. Narrative identity is positively associated with mental health.
- Trial name
- PEPsy-Identity (NCT06464848)
- Testing
- Narrative identity task
- Where
- France
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Schizophrenia
Study on Examination of Therapeutic Efficacy and Potential Mechanisms of Yoga Treatment in Schizophrenia
The aim of this study is to examine whether yoga is efficacious as an add-on treatment for negative symptoms of schizophrenia in a randomized multi-centric trial and also to examine functional brain changes associated with…
- Trial name
- SATYAM (NCT03379480)
- Testing
- Yoga arm
- Where
- India
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health and Neuro Sciences, India
Psychiatric Disorder, Schizophrenia
Improving Physical Health in Patients With Psychiatric Disorders in General Practice (SOFIA)
People with a severe mental illness (SMI) have an increased risk for premature mortality, predominantly due somatic health conditions.
- Conditions
- Psychiatric Disorder, Schizophrenia, Bipolar Disorder, Severe Depression
- Trial name
- SOFIA (NCT04618250)
- Testing
- SOFIA model
- Where
- Denmark
- Volunteers
- 76 people
- Sponsor
- University of Copenhagen
Psychosis
Relationship Between Efficacy of Lumateperone and Brain Glutamate and Dopamine
This study will examine the differential relationships between antipsychotic efficacy and changes in dopaminergic and glutamatergic brain metabolism in lumateperone and risperidone treated early psychosis patients.
- Trial name
- Lumafep (NCT05890768)
- Testing
- Lumateperone, Risperidone
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of New Mexico
Mental Disorders, Child, Mental Disorder in Adolescence
Equine Assisted Services in Children and Adolescents With Mental Illness
Due to an increasing amount of children and adolescents are suffering from mental illnesses i Sweden. Early preventive psychological interventions are important to avoid a long-time use of medicines.
- Conditions
- Mental Disorders, Child, Mental Disorder in Adolescence, Anxiety Disorders, Anxiety
- Trial name
- EASiCAM (NCT05670990)
- Testing
- Equine assisted therapy
- Where
- Sweden
- Sponsor
- Peter Nymberg
Mental Disorder, Recovery, Psychological
Peer-based Recovery Program
Recovery-oriented services are currently the mainstream in the field of mental health around the world. Peer services are an alternative service option promoted by recovery advocates.
- Trial name
- NCT07262411
- Testing
- The Grow to Recovery program-Short Version
- Where
- Taiwan
- Volunteers
- 138 people
- Sponsor
- National Cheng-Kung University Hospital
Postpartum Depression
The Effects of Motherly on Postpartum Depression
Investigators will be test the efficacy of Motherly, a smartphone application (app) to treat depression in women with postpartum Depression.
- Trial name
- NCT05055674
- Testing
- Motherly app, COMVC app
- Volunteers
- 264 people
- Sponsor
- University of Sao Paulo
Schizophrenia
Bifeprunox in the Treatment of Schizophrenia
Study of the long-term efficacy and safety of bifeprunox in the treatment of schizophrenia.
- Trial name
- NCT00193713
- Testing
- bifeprunox
- Sponsor
- Solvay Pharmaceuticals
Sleep Disturbance, Psychotic Disorders
Sleep Disturbances in Patients With Psychotic Symptoms (AkuSleep)
Sleep disturbance is recognized as a major problem for patients with psychosis and is seen in nearly all patients admitted in acute crisis to a psychiatric hospital.
- Trial name
- AkuSleep (NCT04290650)
- Testing
- Modified CBT for insomnia, Treatment as usual
- Where
- Norway
- Volunteers
- 75 people
- Sponsor
- Oslo University Hospital
Schizophrenia, Schizoaffective Disorder
Schizophrenia, Antipsychotic Treatment and the Risk for Diabetes Mellitus
This preliminary study aims to investigate the mechanism of higher rates of type 2 diabetes mellitus in patients with schizophrenia.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Delusional Disorder
- Trial name
- NCT00222807
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Age-Related Macular Degeneration, Allergies
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
To collect, preserve, and/or distribute annotated biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and develop new treatments, diagnostics, and…
- Conditions
- Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease
- Trial name
- NCT05635266
- Testing
- Specimen sample
- Where
- United States
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
Cannabis, Schizophrenia
Family Motivational Intervention in Schizophrenia
Cannabis use by people with schizophrenia is associated with family distress and poor clinical outcomes. Therefore, an Family Motivational Intervention (FMI) was developed to help parents to motivate their child with a diagnoses…
- Trial name
- FMI (NCT01167556)
- Testing
- Family Motivational Intervention
- Where
- Netherlands
- Volunteers
- 147 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Schizophrenia
The Effects of Cannabis Use in People With Schizophrenia on Clinical, Neuropsychological and Physiological Phenotypes
Approximately 25% of people with schizophrenia abuse marijuana. These people may be using marijuana to self-medicate symptoms such as hallucinations (hearing or seeing things that are not heard or seen by others) or delusions…
- Trial name
- NCT01832766
- Testing
- Dronabinol
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Colorado, Denver
Schizophrenia, Schizoaffective Disorder
Stimulating the Brain to Improve Self-Awareness
This study investigates whether Introspective Accuracy (IA) can be improved in individuals with schizophrenia by stimulating the brain via transcranial Direct Current Stimulation (tDCS).
- Trial name
- NCT03370341
- Testing
- active anodal tDCS
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- The University of Texas at Dallas
Schizophrenia, Bipolar I Disorder
Multicenter, Randomized, Comparative and Prospective Study Evaluating the Impact on the Care Path of an Editorial Program Accompanied by Advance Directives in Psychiatry (DAP) for People Suffering From Schizophrenia, Bipolar I Disorder or Schizoaffective Disorder
Severe mental illness is accompanied by cognitive fluctuations that can alter decision-making skills and lead to coerced care. Taking into account, on the one hand, the health, social and economic impact of forced…
- Trial name
- DAiP (NCT03630822)
- Testing
- Psychiatric Advanced Directive, Standard care
- Where
- France
- Volunteers
- 399 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Schizophrenia
A Safety and Tolerability Study of Paliperidone Palmitate Injected in the Shoulder or the Buttock Muscle in Patients With Schizophrenia
The purpose of this study is to evaluate the safety and tolerability of intramuscular injections (to the buttocks or to the shoulders) of paliperidone palmitate in patients with schizophrenia.
- Trial name
- NCT00119756
- Testing
- paliperidone palmitate
- Volunteers
- 253 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Psychotic Depression, Severe Major Depression With Psychotic Features
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
Approximately 450 patients will be randomized to receive mifepristone or placebo for 7 days followed by antidepressant. The purpose is to compare the efficacy of mifepristone followed by antidepressant versus placebo followed by…
- Conditions
- Psychotic Depression, Severe Major Depression With Psychotic Features, Psychosis
- Trial name
- NCT00637494
- Testing
- mifepristone
- Where
- 42 sites in United States
- Volunteers
- 292 people
- Sponsor
- Corcept Therapeutics